1-8 of 8
ganetespib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L. Gordon, BSc, Goutham Narla, MD PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2649.
https://doi.org/10.1182/blood-2018-99-116759
Published: 2018
Journal Articles

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Michael Dennis, MDMRCP,FRCPath, Robert K. Hills, DPhil, Nigel H. Russell, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Ian Thomas, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Sahra Ali, Alan K. Burnett, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3874.
https://doi.org/10.1182/blood.V130.Suppl_1.3874.3874
Published: 2017
Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD
Journal: Blood
Blood (2016) 128 (22): 2827.
https://doi.org/10.1182/blood.V128.22.2827.2827
Published: 2016
Journal Articles

Drug Induced MLL Fusion Degradation Via Hsp90 Inhibition

Sandra Cantilena, MPhil, Nicholas Goulden, MD PhD, Owen Williams, PhD, Jasper de Boer, PhD
Journal: Blood
Blood (2015) 126 (23): 4850.
https://doi.org/10.1182/blood.V126.23.4850.4850
Published: 2015
Journal Articles

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias

Hima Bansal, Sanjay Bansal, Manjeet Rao, Kevin P. Foley, Jim Sang, David A. Proia, Ronald K. Blackman, Weiwen Ying, James Barsoum, Maria R. Baer, Kevin Kelly, Ronan Swords, Gail E. Tomlinson, Minoo Battiwalla, Francis J. Giles, Kelvin P. Lee, Swaminathan Padmanabhan
Journal: Blood
Blood (2010) 116 (22): 4591–4599.
https://doi.org/10.1182/blood-2009-10-247239
Published: 2010
Includes: Supplemental data
Journal Articles

A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies

Jeffrey E. Lancet, MD, B. Douglas Smith, MD, Robert Bradley, Rami S. Komrokji, MD, Florentina Teofilovici, MD, David A. Rizzieri, MD
Journal: Blood
Blood (2010) 116 (21): 3294.
https://doi.org/10.1182/blood.V116.21.3294.3294
Published: 2010
Journal Articles

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies

Swaminathan Padmanabhan, MBBS, MD, Kevin R Kelly, MD, Mark Heaney, MD, PhD, Stephanie Hodges, Suzanne Chanel, RN, Mark Frattini, MD, Ronan Swords, MD, MRCPI, FRCPath, Robert Bradley, Florentina Teofilovici, MD, MS, Daniel J DeAngelo, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2898.
https://doi.org/10.1182/blood.V116.21.2898.2898
Published: 2010
Journal Articles

Preclinical Evaluation of A Potent 2 nd Generation Small-Molecule Hsp90 Inhibitor STA-9090 In Hematological Cell Lines

Weiwen Ying, David Proia, Suqin He, Jim Sang, Kevin Foley, Zhenjian Du, Ronald k Blackman, Yumiko Wada, Lijun Sun, Keizo Koya
Journal: Blood
Blood (2010) 116 (21): 2899.
https://doi.org/10.1182/blood.V116.21.2899.2899
Published: 2010